Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 631

Sort by

Sort Order Select

Journal Articles

A conceptual framework for managing iTTP

Richard J. Benjamin

Blood (2021) 137 (14): 1845–1846.

https://doi.org/10.1182/blood.2021011007

Published: 2021

Journal Articles

AL patients don’t dare go without dara

Angela Dispenzieri

Blood (2020) 135 (18): 1509–1510.

https://doi.org/10.1182/blood.2020005436

Published: 2020

Journal Articles

Results of a Phase II Study of Obinutuzumab in Combination with Lenalidomide in Previously Untreated, High Tumor Burden Follicular Lymphoma (FL)

Loretta J. Nastoupil, MD MSc, Jason R. Westin, MD, Fredrick B. Hagemeister, MD, Hun Ju Lee, Luis Fayad, MD, Felipe Samaniego, MD, Sairah Ahmed, MD, Linda Claret, Raphael E Steiner, MD, Ranjit Nair, MBBS,MD, Simrit Parmar, MBBS, Maria Alma Rodriguez, MD, Michael L. Wang, MD, Michael R Green, PhD, Eric Davis, MD, Sattva S Neelapu, MD, Nathan H Fowler, MD

Blood (2019) 134 (Supplement_1): 125.

https://doi.org/10.1182/blood-2019-129422

Published: 2019

Journal Articles

The Global State of Hematopoietic Stem Cell Transplantation for Multiple Myeloma: An Analysis of the Worldwide Network of Blood and Marrow Transplantation (WBMT) Database and the Global Burden of Disease Study

Blood (2019) 134 (Supplement_1): 412.

https://doi.org/10.1182/blood-2019-126837

Published: 2019

Journal Articles

A US Budget Impact Model for Selinexor in Combination with Dexamethasone for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM)

Ian Gould, PhD, Jan Bassali, PharmD, Jyotsna Mehta, Jatin Shah, MD, Dee Dee Mladsi, BA

Blood (2019) 134 (Supplement_1): 5824.

https://doi.org/10.1182/blood-2019-125997

Published: 2019

Journal Articles

First Clinical Study of the B-Cell Maturation Antigen (BCMA) 2+1 T Cell Engager (TCE) CC-93269 in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Interim Results of a Phase 1 Multicenter Trial

Luciano J. Costa, MD PhD, Sandy W. Wong, Arancha Bermúdez, Javier de la Rubia, María-Victoria Mateos, Enrique M. Ocio, Paula Rodríguez-Otero, Jesús San-Miguel, Shaoyi Li, Rafael Sarmiento, Pilar Lardelli, Allison Gaudy, Isaac Boss, Lisa M. Kelly, Michael R. Burgess, Kristen Hege, William I. Bensinger

Blood (2019) 134 (Supplement_1): 143.

https://doi.org/10.1182/blood-2019-122895

Published: 2019

Journal Articles

Hemophilia A Inhibitor Subjects Show Unique PBMC Gene Expression Profiles That Include up-Regulated Innate Immune Modulators

Ahmad Faisal Karim, PhD, Anthony R. Soltis, PhD, Nadia P Ewing, MD, Clifton L. Dalgard, PhD, Matthew D. Wilkerson, PhD, Kathleen P. Pratt, PhD

Blood (2019) 134 (Supplement_1): 160.

https://doi.org/10.1182/blood-2019-124855

Published: 2019

Journal Articles

Changing Trends in the Risk Factors of Secondary Primary Malignancies after Autologous Stem Cell Transplantation for Multiple Myeloma before and after the Introduction of Proteasome Inhibitors/Immunomodulatory Agents

Hiroyuki Takamatsu, MD PhD, Shohei Mizuno, MD PhD, Tsutomu Takahashi, MD PhD, Shin-Ichi Fuchida, MD PhD, Ichiro Hanamura, MD PhD, Fumihiko Nakamura, MD PhD, Takehiko Mori, MD PhD, Yuta Katayama, MD PhD, Noriko Doki, MD PhD, Nobuhiro Tsukada, MD PhD, Tatsuo Ichinohe, Yoshinobu Kanda, MD PhD, Yoshiko Atsuta, MD PhD, Kazutaka Sunami, MD PhD

Blood (2019) 134 (Supplement_1): 4358.

https://doi.org/10.1182/blood-2019-123607

Published: 2019

Journal Articles

NKTR-255, a Polymer-Conjugated IL-15 Enhances Antibody-Dependent Cellular Cytotoxicity Mediated By NK Cells in a B Cell Lymphoma Model

Takahiro Miyazaki, Saul Kivimäe, Marlene Hennessy, Rhoneil Pena, Phi Quach, Andrew Moffet, Wildaliz Nieves, Ping Zhang, Mario Q. Marcondes, MD PhD, Loui Madakamutil, Jonathan Zalevsky

Blood (2019) 134 (Supplement_1): 5302.

https://doi.org/10.1182/blood-2019-127771

Published: 2019

Journal Articles

Carfilzomib Based Regimens for Treatment of Newly Diagnosed Multiple Myeloma: A Systematic Review

Maimoona Khan, MBBS, Asma Waheed, MBBS, Rida Ul Jannat, MBBS, Arafat Ali Ali Farooqui, MD, Muhammad Saad Farooqi, MD, Ali Younas Khan, MD, Madeeha Shafqat, Muhaddis Ejaz Ahmad, MD, Muhammad Abdullah Yousaf, MBBS, MD, Tariq Iqtidar Sadiq Syed, MD, Syed Maaz Abdullah, MBBS, Sravanthi Kotapati, MBBS, Irbaz Riaz, MDMMSc, Faiz Anwer, MD

Blood (2019) 134 (Supplement_1): 5588.

https://doi.org/10.1182/blood-2019-128833

Published: 2019

Journal Articles

Racial Differences in High-Risk Cytogenetic Mutations and Outcomes in Multiple Myeloma

Ben A Derman, MDBA, Meytal Chernoff, BS, Andrzej Jakubowiak, MD PhD, Brian C.-H. Chiu, PhD

Blood (2019) 134 (Supplement_1): 5494.

https://doi.org/10.1182/blood-2019-126304

Published: 2019

Journal Articles

Salvage Autologous Stem Cell Transplant in Relapsed Myeloma Patients in the Era of Modern Treatment: Is There a Role?

Sahar Khan, Eshetu G Atenafu, M.Sc., P.Stat, Christine I Chen, MD, Esther Masih-Khan, PhD, Lavinia Aileen Jeyanathan, Anca Prica, MD, Donna E Reece, MD, Rodger E Tiedemann, MBChB, PhD, Suzanne Trudel, MD, Vishal Kukreti, MD

Blood (2019) 134 (Supplement_1): 5704.

https://doi.org/10.1182/blood-2019-130733

Published: 2019

Journal Articles

Quality of Life in Patients with Multiple Sclerosis after Autologous Hematopoietic Stem Cell Transplantation

Juan Carlos Olivares-Gazca, MD, Iván Murrieta-Álvarez, MD, Jesús Mauricio Olivares-Gazca, MD, Yarely Itzayana García-Navarrete, MD, Yahveth Cantero-Fortiz, MD, Andrés A. León-Peña, MD, Guillermo J. Ruiz-Delgado, MD FACP, Guillermo J. Ruiz-Arguelles, FRCP, MACP

Blood (2019) 134 (Supplement_1): 5708.

https://doi.org/10.1182/blood-2019-129031

Published: 2019

Journal Articles

Three Drug Regimens for Newly Diagnosed Multiple Myeloma Transplant-Ineligible Elderly Patients - a Systematic Review

Abdul Aziz Siddiqui, MD, Kazi Najamus-saqib Khan, Arafat Ali Farooqui, MD, Muhammad Saad Farooqi, MD, Muhammad Junaid Tariq, MD, Faiz Anwer, MD

Blood (2019) 134 (Supplement_1): 5574.

https://doi.org/10.1182/blood-2019-132095

Published: 2019

Journal Articles

Profile of Long-Term Survivors in Multiple Myeloma

Blood (2019) 134 (Supplement_1): 5522.

https://doi.org/10.1182/blood-2019-127519

Published: 2019

Journal Articles

VTE Incidence in RRMM Patients Treated with NOVEL Agents: A Monocentric Real Life Experience

Gaetano Giuffrida, MD, Concetta Conticello, MD, Valeria Calafiore, Enrica Antonia Martino, MD, Silvia Giamporcaro, MD, Alessandra Romano, MD PhD, Francesco Di Raimondo, MD

Blood (2019) 134 (Supplement_1): 4972.

https://doi.org/10.1182/blood-2019-131015

Published: 2019

Journal Articles

Safety and Efficacy of Combined Ruxolitinib and Thalidomide in Patients with Myelofibrosis: A Phase II Study

Raajit K. Rampal, MD PhD, Srdan Verstovsek, MD PhD, Sean M. Devlin, PhD, Amber C. King, PharmD, BCOP, Eytan M. Stein, MD, Naveen Pemmaraju, MD, Michael J. Mauro, MD, Tapan M. Kadia, MD, Guillermo Montalban-Bravo, MD, Kelsey Alvarez, RN, Nicole Ard, Tawni Goodman, Bria Taylor, Prithviraj Bose, MD

Blood (2019) 134 (Supplement_1): 4163.

https://doi.org/10.1182/blood-2019-127661

Published: 2019

Journal Articles

A Prospective Disease Registry of Patients with Mantle Cell Lymphoma Treated with Novel Agents: Treatment Patterns, Outcomes, and Patient-Reported Health-Related Quality of Life

Chaitra Ujjani, MD, Anthony R. Mato, MDMSCE, Jonathon B. Cohen, MDMS, Jakub Svoboda, MD, David Andorsky, MD, Andre Goy, MD, Michael L. Wang, MD, Anita Kumar, MD, Peggy Ann Torney, MS, Michelle Dawson, PhD, Cynthia Elesinmogun, PharmD, Shaum M Kabadi, PhDMPH, Brian Seal, MBA, PhD, John M. Pagel, MD PhD DSc, Scott D Ramsey, MD PhD

Blood (2019) 134 (Supplement_1): 5892.

https://doi.org/10.1182/blood-2019-122845

Published: 2019

Journal Articles

Elotuzumab in Combination with an Immunomodulatory Agent (IMID) in Patients with Multiple Myeloma Refractory to Imids and/or Daratumumab: A Single-Institution Analysis

Ariel F Grajales-Cruz, MD, Cristian Ivan Rodriguez Arocho, MD, Ashley Rose, MD, Jamie Shapiro, PharmD, Elizabeth Finley-Oliver, Kenneth H. Shain, MD PhD, Jason B. Brayer, PhDMD, Taiga Nishihori, MD, Leonel Ochoa, MD, Omar Alexis Castaneda Puglianini, MD, Melissa Alsina, MD, Rachid Baz, MD

Blood (2019) 134 (Supplement_1): 3183.

https://doi.org/10.1182/blood-2019-129021

Published: 2019

Journal Articles

Safety and Preliminary Clinical Activity of REGN5458, an Anti-Bcma x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma

Dennis Cooper, MD, Deepu Madduri, MD, Suzanne Lentzsch, MD PhD, Sundar Jagannath, Jingjin Li, PhD, Anita Boyapati, PhD, Lieve Adriaens, PharmD, Dhruti Chokshi, BS, Min Zhu, PhD, Israel Lowy, MD PhD, David M. Weinreich, MD, George D. Yancopoulos, MD PhD, Manish Sharma, MD, Maria Karasarides, PhD, David Sternberg, MD PhD

Blood (2019) 134 (Supplement_1): 3176.

https://doi.org/10.1182/blood-2019-126818

Published: 2019

NARROW

A conceptual framework for managing iTTP

AL patients don’t dare go without dara

Results of a Phase II Study of Obinutuzumab in Combination with Lenalidomide in Previously Untreated, High Tumor Burden Follicular Lymphoma (FL)

The Global State of Hematopoietic Stem Cell Transplantation for Multiple Myeloma: An Analysis of the Worldwide Network of Blood and Marrow Transplantation (WBMT) Database and the Global Burden of Disease Study

A US Budget Impact Model for Selinexor in Combination with Dexamethasone for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM)

First Clinical Study of the B-Cell Maturation Antigen (BCMA) 2+1 T Cell Engager (TCE) CC-93269 in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Interim Results of a Phase 1 Multicenter Trial

Hemophilia A Inhibitor Subjects Show Unique PBMC Gene Expression Profiles That Include up-Regulated Innate Immune Modulators

Changing Trends in the Risk Factors of Secondary Primary Malignancies after Autologous Stem Cell Transplantation for Multiple Myeloma before and after the Introduction of Proteasome Inhibitors/Immunomodulatory Agents

NKTR-255, a Polymer-Conjugated IL-15 Enhances Antibody-Dependent Cellular Cytotoxicity Mediated By NK Cells in a B Cell Lymphoma Model

Carfilzomib Based Regimens for Treatment of Newly Diagnosed Multiple Myeloma: A Systematic Review

Racial Differences in High-Risk Cytogenetic Mutations and Outcomes in Multiple Myeloma

Salvage Autologous Stem Cell Transplant in Relapsed Myeloma Patients in the Era of Modern Treatment: Is There a Role?

Quality of Life in Patients with Multiple Sclerosis after Autologous Hematopoietic Stem Cell Transplantation

Three Drug Regimens for Newly Diagnosed Multiple Myeloma Transplant-Ineligible Elderly Patients - a Systematic Review

Profile of Long-Term Survivors in Multiple Myeloma

VTE Incidence in RRMM Patients Treated with NOVEL Agents: A Monocentric Real Life Experience

Safety and Efficacy of Combined Ruxolitinib and Thalidomide in Patients with Myelofibrosis: A Phase II Study

A Prospective Disease Registry of Patients with Mantle Cell Lymphoma Treated with Novel Agents: Treatment Patterns, Outcomes, and Patient-Reported Health-Related Quality of Life

Elotuzumab in Combination with an Immunomodulatory Agent (IMID) in Patients with Multiple Myeloma Refractory to Imids and/or Daratumumab: A Single-Institution Analysis

Safety and Preliminary Clinical Activity of REGN5458, an Anti-Bcma x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only